Rotigotine Transdermal Matrix with Silicone Adhesive and Paraffin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal therapeutic systems for administering rotigotine face challenges such as crystallization of the active ingredient, unsatisfactory adhesive strength, and stickiness, particularly when using amine-resistant silicone adhesives, which can lead to manufacturing difficulties and inconsistent drug delivery.
Innovation Solution
Incorporating a small amount of paraffin into the matrix layer of the transdermal therapeutic system, along with non-amine-resistant silicone adhesives, and using a specific weight ratio of rotigotine to polyvinylpyrrolidone in a solid dispersion, prevents crystallization and enhances adhesive strength and stickiness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If amine-resistant silicone adhesives are used in the matrix layer, then the adhesive strength is improved, but the stickiness deteriorates
Solution Approach 1:
The patent combines amine-resistant silicone adhesive with paraffin and polyvinylpyrrolidone to create a composite matrix layer. This composite formulation maintains the adhesive strength provided by the silicone adhesive while the paraffin and polyvinylpyrrolidone components restore and enhance the stickiness, resolving the contradiction between strength and ease of operation.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the silicone adhesive by incorporating paraffin (0.1-10 wt%) and polyvinylpyrrolidone (1-20 wt%) into the matrix layer. These parameter changes alter the adhesive properties to simultaneously achieve both strong adhesion and adequate stickiness, which were mutually exclusive in the original formulation.
2Productivity
If rotigotine is formulated in a polymer matrix, then the drug delivery is improved, but crystallization occurs leading to manufacturing difficulties
Solution Approach 1:
The patent introduces polyvinylpyrrolidone as an intermediary substance that forms a solid dispersion with rotigotine. This intermediary prevents crystallization of the active ingredient while maintaining its drug delivery properties, thereby enabling easier manufacturing without sacrificing therapeutic effectiveness.
Solution Approach 2:
The patent changes the physical state parameters of rotigotine by formulating it as a solid dispersion in polyvinylpyrrolidone rather than a crystalline form. This parameter change prevents crystallization during manufacturing while preserving the drug's permeation and delivery characteristics.
3Ease of manufacture
If non-amine-resistant silicone adhesives are used, then the manufacturing process is simplified, but adhesive strength becomes insufficient
Solution Approach 1:
The patent creates a composite matrix layer combining non-amine-resistant silicone adhesive with paraffin and polyvinylpyrrolidone. This composite formulation maintains the manufacturing simplicity of non-amine-resistant adhesives while the combined components provide sufficient adhesive strength through synergistic effects.
Solution Approach 2:
The patent modifies the adhesive properties parameters by adding paraffin (0.1-10 wt%) and polyvinylpyrrolidone (1-20 wt%) to the non-amine-resistant silicone adhesive. These parameter changes enhance the adhesive strength without complicating the manufacturing process, as the additives can be incorporated during standard formulation steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides improved adhesive strength, stickiness, and storage stability, ensuring consistent drug delivery and simplifying the manufacturing process while maintaining effective skin permeation of rotigotine.
Implementation Method 1
Incorporating a small amount of paraffin into the matrix layer of the transdermal therapeutic system, along with non-amine-resistant silicone adhesives, and using a specific weight ratio of rotigotine to polyvinylpyrrolidone in a solid dispersion, prevents crystallization
Implementation Method 2
The matrix layer (2) contains one or more non-amine-resistant pressure-sensitive silicone adhesives in an amount of more than 50 wt.%, based on the total weight of the pressure-sensitive adhesives of the matrix layer (2)
Implementation Method 3
the rotigotine in the matrix layer (2) is present substantially in a non-crystalline form in the dispersed phase of a solid dispersion comprising a polyvinylpyrrolidone
Implementation Method 4
maintaining effective skin permeation of rotigotine
Data Source
Figure 1(A)~1(B)
Figure 2
Figure 3
AI summary
The invention relates to a transdermal therapeutic system (TTS) for administering the ingredient rotigotine, comprising a matrix layer which contains rotigotine, one or more non-amine-resistant silicone adhesives in a quantity of more than 50 wt.% based on the total weight of the pressure-sensitive adhesive of the matrix layer, and paraffin. The invention also relates to a method for producing same. The transdermal therapeutic system according to the invention is suitable, in particular, for treating Parkinson's disease.